Ascendis Pharma A/S: H.C. Wainwright cuts target price to $344 from $345

On August 31, 2026, H.C. Wainwright & Co. reiterated a 'Buy' rating for Ascendis Pharma A/S (ASND), maintaining adjusted price target of $344, down from $345 previously. The firm cited continued confidence in the company’s growth potential and its innovative TransCon technology platform, which is being applied to develop therapies in endocrinology and oncology.

Currently, the stock trades at $247.96, with a price-to-earnings (P/E) ratio of 19.5x, lower than its 5-year median of 24.74x. This suggests the stock may be undervalued relative to its historical performance. Ascendis Pharma, with a market capitalization of $16.26 billion, derives most of its revenue from the United States and is positioned as a key player in the biotechnology sector.

The GF Score™ for Ascendis Pharma stands at 41/100, reflecting moderate overall performance, with strong growth potential but a low valuation rank. Insider activity has also been notable, with $681,950 in insider purchases over the last three months, signaling confidence in the company’s future.

While the price target was slightly reduced, the 'Buy' rating underscores the firm’s belief in the company’s long-term prospects and its ability to deliver value to shareholders.